Andreas Heil
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Journal: Cells
Published: March 31, 2022
Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 19, 2019
Response to Comment by Calderón de la Barca and Sigala-Robles on Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin.
Journal: Journal of agricultural and food chemistry
Published: December 28, 2017
Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin.
Journal: Journal of agricultural and food chemistry
Published: July 20, 2017
Synthesis and solid state NMR characterization of novel peptide/silica hybrid materials.
Journal: Solid state nuclear magnetic resonance
Published: June 26, 2015
On the contribution of biomass burning to POPs (PAHs and PCDDs) in air in Africa.
Journal: Environmental science & technology
Published: September 26, 2013
PHIP-label: parahydrogen-induced polarization in propargylglycine-containing synthetic oligopeptides.
Journal: Chemical communications (Cambridge, England)
Published: July 27, 2013
Differences in the inhibition of coagulation factor XIII-A from animal species revealed by Michael Acceptor- and thioimidazol based blockers.
Journal: Thrombosis research
Published: November 19, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026